 It is possible that hematological malignancies associated with "ETV6" gene fusions to either the "SYK" or "FRK" tyrosine kinase genes may someday be shown susceptible to tyrosine kinase inhibitor therapy.However, children with "ETV6-RUNX1"-associated acute lymphoblastic leukemia are in an especially good-risk subgroup and therefore have been almost uniformly treated with standard-risk chemotherapy protocols.Hematological malignancies associated with "ETY6" gene fusions to other transcription factor genes appear to reflect a loss or gain in function of "ETV6" and/or the other genes in regulating expression of their target genes; this results in the formation or lack of formation of products which influence cell growth, proliferation, and/or survival.